GO
| HSI1 | 26,545.10 | +0.25 | 376.81B |
| HSCEI1 | 9,472.35 | +15.83 | 129.31B |
| Back Zoom + Zoom - Block Traded | |
|
2025-09-17 10:30:20 ALI HEALTH (00241.HK)'s share price rocketed approx. 27% in total since the announcement of its FY2025 results in May, outperforming its peers by 8 ppts, JPMorgan released a research report saying. The broker attributed this mainly to investors' positive reaction to the recent updates in online retail sales policies for prescription drugs. Given that this is essentially a guideline with no substantial difference from existing policies, its impact weighs more on sentiment, in JPMorgan's view. JPMorgan raised its FY2026/ 2027 revenue forecasts for ALI HEALTH by 4% each, reflecting the synergy in user traffic and overall GMV from Taobao quick e-commerce. The broker also lifted its FY2026/ 2027 adjusted EPS forecasts by 3%/ 4%, reflecting the marketing cost savings on Taobao's high subsidies into quick e-commerce, partially offset by investments due to business collaboration. Therefore, JPMorgan added its target price from $5 to $6.5, equivalent to a FY2026 projected PS ratio of 2.5x, with rating kept at Neutral. ~ AASTOCKS Financial News Website: www.aastocks.com | |